[1] |
LU Renquan, LIU Guangyu, YANG Wentao, GUO Lin, GUAN Ming, SHAO Zhimin, XU Dazhi, NI Ming, TANG Feng, WANG Chaofu, LOU Jiatao, SUN Fenyong, XING Jinliang, PAN Yueyin.
Application consensus of peripheral blood HER2 gene amplification detection (digital PCR) in anti-HER2 therapy
[J]. China Oncology, 2022, 32(1): 90-96.
|
[2] |
ZHU Yihui, LI Ting, HU Xichun.
Clinical research progress and prospect of trastuzumab deruxtecan
[J]. China Oncology, 2021, 31(8): 754-761.
|
[3] |
DING Gaofeng, GUO Leiming, LU Yufei.
The relationship between expressions of HER2 and BRCA1 and radiotherapy sensitivity in breast cancer patients
[J]. China Oncology, 2021, 31(7): 589-595.
|
[4] |
GUO Ye , ZHANG Chenping .
Expert consensus on the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck with anti-EGFR monoclonal antibody (2021 edition)
[J]. China Oncology, 2021, 31(12): 1220-1232.
|
[5] |
ZHANG Jinzhong , LI Yueqi , SHI Ke , YANG Liang , GUO Dan .
Expression and clinical significance of PLK4 gene in esophageal squamous cell carcinoma and its effect on cell proliferation, invasion and migration
[J]. China Oncology, 2021, 31(12): 1185-1193.
|
[6] |
HE Xi, JIAO Xiaodong, ZANG Yuansheng.
Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(1): 69-75.
|
[7] |
PAN Jian, WEI Yu, WU Junlong, WAN Fangning, YE Dingwei, ZHU Yao.
Correlation of HSD3B1 gene polymorphism and clinicopathological characteristics of prostate cancer
[J]. China Oncology, 2020, 30(9): 650-655.
|
[8] |
ZHU Lihua , NI Tingting , FAN Xingwen , WU Kailiang .
Comparison of prognostic scoring systems in patients with EGFR-mutant lung cancer and brain metastases
[J]. China Oncology, 2020, 30(8): 605-610.
|
[9] |
SHI Zhiqiang , QIU Pengfei , LIU Yanbing , ZHAO Tong , SUN Xiao , CHEN Peng , WANG Chunjian , ZHANG Zhaopeng , CONG Binbin , WANG Yongsheng .
Selective elimination of axillary surgery staging after neoadjuvant chemotherapy for HER2 positive and triple-negative breast cancer
[J]. China Oncology, 2020, 30(3): 186-191.
|
[10] |
LIU Yongzhi, ZHAO Yonghua, JIANG Hai, BAO Liping, WU Wei, SUN Qiang, JIANG Huichuan, JIA Zhaobo, HAO Shichao.
Clinicopathological characteristics and survival analysis of patients with mucinous breast carcinoma based on SEER database
[J]. China Oncology, 2019, 29(12): 955-960.
|
[11] |
WANG Xiaoshen, HU Chaosu.
Anti-EGFR monoclonal antibodies combined with other modalities in treatment of head and neck squamous cell carcinoma
[J]. China Oncology, 2018, 28(12): 881-887.
|
[12] |
CHEN Dongfang, TENG Haohua, ZHAO Ruiying, et al.
Small cell lung cancer transformation from T790M-mutant lung adenocarcinoma following osimertinib treatment
[J]. China Oncology, 2018, 28(12): 935-939.
|
[13] |
DAI Xi, LI Guoping, YANG Xiaoqiong, et al.
Effects of Lyn kinase on EGFR signaling pathway in lung adenocarcinoma
[J]. China Oncology, 2018, 28(1): 43-49.
|
[14] |
ZHU Wenliang, LI Jing, LIANG Xinqiang, et al.
The association between plasma TGF-α levels and EGFR-TKI treatment sensitivity and prognosis in NSCLC patients with EGFR mutation
[J]. China Oncology, 2017, 27(5): 389-395.
|
[15] |
ZHANG Jie, ZHENG Hui, LU Renquan, et al.
The effect of different expression levels of HER-2 on the biological characteristics of breast cancer cells
[J]. China Oncology, 2017, 27(3): 201-206.
|